Assessing SI-BONE (SIBN) Valuation After Jim Cramer Endorsements And New Analyst Coverage

Jim Cramer’s repeated description of SI-BONE (SIBN) as a “great, great speculation,” combined with fresh buy-side analyst coverage, has pushed this small medical device name into the spotlight for many retail investors.

See our latest analysis for SI-BONE.

Those comments and the fresh research coverage are landing on a stock that has already caught some attention, with a 90 day share price return of 36.81% and a 1 year total shareholder return of 48.98%. This comes even though the latest share price of $20.44 sits slightly below its recent levels after a 1 day share price decline of 2.11%.

If SI-BONE’s move has you looking across the sector, this could be a useful moment to scan other healthcare stocks that might fit a similar thesis or offer a different risk profile.

So with SI-BONE up strongly over the past year, fresh analyst coverage and a recent pullback to $20.44, is this still an underappreciated growth story, or are markets already pricing in what comes next?

With SI-BONE last closing at $20.44, the most followed narrative places fair value at $25, implying meaningful upside based on its growth and margin potential.

Expanding product portfolio and successful recent launches (e.g., iFuse TORQ, Granite 9.5, TNT) are opening new addressable markets within musculoskeletal care and facilitating further penetration into outpatient and ASC settings, supporting top-line revenue expansion and sustainable long-term procedure growth.

Read the complete narrative.

Curious what kind of revenue ramp, margin shift, and future P/E multiple would need to line up for that fair value to make sense? The narrative refers to specific growth rates, margin inflection and a richer earnings multiple than the broader medical equipment space. The exact mix of those assumptions is where the story becomes more detailed.

Result: Fair Value of $25 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this story can crack if U.S. reimbursement tightens or if surgeon adoption slows. This could pressure margins and delay any path toward consistent profitability.

Find out about the key risks to this SI-BONE narrative.

If you see the data differently or prefer to do your own work, you can pull the key inputs together and build a custom view in minutes: Do it your way.

A great starting point for your SI-BONE research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.